PCVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vaxcyte Inc (PCVX) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and upcoming catalysts, the lack of immediate trading signals, weak financial performance, and neutral trading sentiment suggest waiting for more favorable conditions.
The stock shows bullish momentum with MACD positively expanding and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). However, RSI is in the neutral zone at 76.332, and the stock is near its resistance level (R1: 61.683).
Analyst ratings are largely positive with increased price targets and optimism around VAX-31 Phase III data. Upcoming catalysts include Phase 3 adult data and Phase 2 pediatric readouts.
The company's financials remain weak with no revenue, significant net losses (-$246.5M in Q4 2025), and negative EPS (-1.81). Additionally, there is no recent news or significant insider/hedge fund activity.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$246.5M (though improved by 79.83% YoY), and an EPS of -1.81 (up 79.21% YoY). Gross margin remains at 0%.
Analysts are bullish overall. TD Cowen raised the price target to $75, Goldman Sachs to $67, BofA to $133, and BTIG to $89, all maintaining Buy ratings except Goldman Sachs, which remains Neutral. Analysts view VAX-31 as a key de-risking catalyst for the company's future.
